Image of hexagons in various sizes

Jamie Moore Elected as President; Mark Schenerman Elected as Vice President to CASSS Board of Directors

Home / News / News

December 15, 2023
Company logo with text 'CASSS Sharing Science Solutions'

CASSS – Sharing Science Solutions is pleased to announce that Jamie Moore, SVP, Global Head of Technical Development for Gilead Sciences, and Mark Schenerman, President CMC Biotech-MAS Consulting, have been elected President and Vice President, respectively, to the CASSS Board of Directors. CASSS board officers are elected by their fellow board members to two-year terms.

Image of female with text 'CASSS President Jamie Moore'

During her presidency, Moore looks forward to working with the CASSS Board of Directors and staff to examine additional opportunities for CASSS to facilitate the sharing of resources, information, and best practices in order to advance scientific knowledge and solve problems. Specifically, the Board will be looking at new and exciting ways to fulfill CASSS’s core objectives of enabling regulatory capacity building, increasing knowledge-sharing opportunities, and expanding global access to these important elements for both legacy and emerging biopharmaceutical products. Moore shared, “I am both humbled and honored to serve the CASSS community in this new role. I recently attended the CMC Strategy Forum in Japan and experienced firsthand how CASSS enabled an environment to foster global harmonization.  I am energized to keep this momentum going, building on the catalyst of the pandemic to further accelerate scientific exchange, problem-solving, and global convergence. Ultimately, we hope CASSS can play a key role in enabling the delivery of high-quality medicine to patients around the world with urgency and efficiency.” 

Jamie Moore is currently SVP, Global Head of Technical Development at Gilead Sciences. Prior to that, Moore was at CytomX Therapeutics as the Senior Vice President, Head of Protein & Process Science and Manufacturing. Moore also spent 20 years at Genentech, a Member of the Roche Group in various leadership roles. After receiving her Bachelor of Science degree in chemistry at Graceland University, Jamie received her Ph.D. from the University of California, San Francisco.

Moore’s volunteer positions with CASSS are extensive but highlights include serving as Industry Co-Chair of WCBP and committee member for the North America CMC Strategy Fora. She was also a long-time committee member and symposium chair for the International Symposium on Higher Order Structure of Protein Therapeutics (HOS).

Image of male with text 'CASSS Vice President Mark Schenerman'

In other changes to CASSS volunteer leadership, Mark Schenerman was elected Vice President and Secretary. Schenerman is currently President of CMC Biotech-MAS Consulting and recently became the Graduate Program Director in Biotechnology for the University of Maryland Baltimore County. He has also been an Adjunct Professor at Johns Hopkins University – Pharmacology and Molecular Medicines for the last 5 years. Prior to that, Schenerman spent more than 20 years in various roles in pharmaceutical development and regulatory processes at MedImmune. After receiving his Bachelor of Science degree in medical technology, Mark received his PhD from the University of Florida.

Schenerman’s volunteer positions with CASSS are extensive but highlights include serving as the Industry Co-Chair of WCBP, committee member for CMC Strategy Fora, helped start many programs including Bioassays, Higher Order Structure, DC Discussion Group, and CASSS Consultants' Network. He has also spearheaded CASSS’ involvement in the Hopkins Biotech Network Mentor Program. He has also been recognized as a CASSS Distinguished Fellow for his outstanding contributions to CASSS, the community, and the industry overall. 

New board leadership positions and board members will begin their terms in January 2024.